Lumida
/SLDB
⌘K
Solid Biosciences Inc

Solid Biosciences Inc

SLDB
$9.16USD-1.51%-0.14 today

MARKET CAP

982.2M

P/E (TTM)

FWD P/E

DAY RANGE

$9 – $9

52W RANGE

$4
$11

AI Summary

Stalk
Buy NowMedium

The stock is in a Stage 2 advancing trend with a clear sequence of higher highs and higher lows since mid-July, supported by rising EMAs and positive momentum. Medium-term bias remains bullish on the active higher-highs/higher-lows structure. Short-term conditions are favorable as price tightly tracks above rising 9 and 20 EMAs without exhaustion, presenting an opportunity to buy now. Key caution points include the overhead resistance zone around $8.92–$9.08 and an RSI approaching overbought, which could trigger a pullback.

  • $377.7M cash reserves fund R&D through mid-2028
  • Phase 3 IMPACT DUCHENNE dosing initiated for SGT-003
  • Pre-revenue status and $54.8M Q2 loss strain liquidity
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2018FY 2019FY 2021FY 2022TREND
Sales, Adj.$0$0$13.6M$8.1M
YoY %-40.6%
P / Sales13.7x5.9x
EV / Sales6.7x-7.3x
Gross Profit, Adj.$0$0$13.6M$8.1M
YoY %-40.6%
Margin %100.0%100.0%
EV / Gross Profit6.7x-7.3x
EBITDA, Adj.$-74.1M$-116.5M$-69.3M$-96.9M
YoY %-57.2%+16.1%-39.8%
Margin %-508.7%-1196.8%
EV / EBITDA-11.1x-1.1x-1.3x0.6x
EBIT$-75.7M$-119.3M$-72.3M$-106.5M
YoY %-57.6%+18.3%-47.3%
Margin %-530.5%-1315.2%
EV / EBIT-10.8x-1.1x-1.3x0.6x
Net Income$-74.8M$-117.2M$-72.2M$-86.0M
YoY %-56.7%+18.2%-19.1%
Net Margin-530.0%-1062.3%
EPS (GAAP)-$33.75-$43.65-$10.14-$10.10
YoY %-29.3%+60.2%+0.4%